orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world.
Company profile
Ticker
ORTX
Exchange
Website
CEO
Bobby Gaspar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Orchard Rx Ltd
SEC CIK
Corporate docs
Subsidiaries
Orchard Therapeutics (Europe) Limited • Orchard Therapeutics (Netherlands) B.V. • Orchard Therapeutics (France) SAS • Orchard Therapeutics (Germany) GmbH • Orchard Therapeutics (Switzerland) GmbH • Orchard Therapeutics (Sweden) AB ...
ORTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
5 Feb 24
EFFECT
Notice of effectiveness
31 Jan 24
EFFECT
Notice of effectiveness
31 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Jan 24
POS AM
Prospectus update (post-effective amendment)
24 Jan 24
Transcripts
ORTX
Earnings call transcript
2023 Q2
3 Aug 23
ORTX
Earnings call transcript
2022 Q4
6 Mar 23
ORTX
Earnings call transcript
2022 Q3
14 Nov 22
ORTX
Earnings call transcript
2022 Q1
12 May 22
ORTX
Earnings call transcript
2021 Q4
30 Mar 22
ORTX
Earnings call transcript
2020 Q2
8 Aug 20
ORTX
Earnings call transcript
2020 Q1
9 May 20
ORTX
Earnings call transcript
2019 Q4
29 Feb 20
ORTX
Earnings call transcript
2019 Q3
9 Nov 19
ORTX
Earnings call transcript
2019 Q2
11 Aug 19
Latest ownership filings
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
FMR LLC
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
Beryl Capital Management LLC
8 Feb 24
4
Alicia Secor
24 Jan 24
4
JAMES A GERAGHTY
24 Jan 24
4
FRANK E THOMAS
24 Jan 24
4
Charles A Rowland Jr
24 Jan 24
4
Joanne T. Beck
24 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.47 mm | 23.47 mm | 23.47 mm | 23.47 mm | 23.47 mm | 23.47 mm |
Cash burn (monthly) | 4.93 mm | 4.77 mm | 11.45 mm | 9.56 mm | 7.96 mm | 7.78 mm |
Cash used (since last report) | 33.62 mm | 32.52 mm | 77.98 mm | 65.14 mm | 54.25 mm | 52.97 mm |
Cash remaining | -10.15 mm | -9.05 mm | -54.51 mm | -41.67 mm | -30.78 mm | -29.51 mm |
Runway (months of cash) | -2.1 | -1.9 | -4.8 | -4.4 | -3.9 | -3.8 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 31 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 45.03 bn |
Total shares | 35.69 mm |
Total puts | 1.20 k |
Total calls | 16.90 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Zentree Investments | 15.96 mm | $0.00 |
CHI Advisors | 12.32 mm | $14.03 bn |
Flynn James E | 3.16 mm | $0.00 |
Deep Track Capital | 2.04 mm | $15.78 bn |
FHI Federated Hermes Inc - Ordinary Shares | 869.33 k | $6.72 bn |
Deerfield Management | 316.17 k | $2.44 bn |
Platinum Investment Management | 248.46 k | $1.92 bn |
Mariner | 192.25 k | $1.49 bn |
Acadian Asset Management | 120.66 k | $936.00 k |
Renaissance Technologies | 114.82 k | $888.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Curnutte John T | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.495 | 105,000 | 51.98 k | 0 |
24 Jan 24 | Curnutte John T | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.475 | 46,000 | 21.85 k | 0 |
24 Jan 24 | Altschuler Steven | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.495 | 105,000 | 51.98 k | 0 |
24 Jan 24 | Altschuler Steven | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.475 | 46,000 | 21.85 k | 0 |
24 Jan 24 | Bobby Gaspar | Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 366,158 | 0.00 | 0 |
24 Jan 24 | Bobby Gaspar | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.58 | 581,590 | 337.32 k | 0 |
24 Jan 24 | Bobby Gaspar | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.464 | 563,410 | 261.42 k | 0 |
24 Jan 24 | Bobby Gaspar | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.574 | 427,360 | 245.30 k | 0 |
24 Jan 24 | Bobby Gaspar | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.459 | 422,630 | 193.99 k | 0 |
24 Jan 24 | Bobby Gaspar | Stock Option Ordinary Shares | Sale back to company | Dispose D | No | No | 0.58 | 55,000 | 31.90 k | 0 |
Press releases
ORI Capital Raises $260 Million for Second Life Sciences Fund
22 Feb 24
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
5 Feb 24
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
2 Feb 24
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
25 Jan 24